The Institute of Safe Medication Practices (ISMP), in its April 2013 report, revealed that 1,723 very alarming adverse events from July 1, 2011 to June 30, 2012 have been received by the Food and Drug Administration (FDA) involving incretin mimetic type of diabetes medications. A total of 831 cases were for pancreatitis, 105 cases for cancer of the pancreas, 32 cases for thyroid cancer, and 101 patients reported sensitivity reactions.
Of this number, 612 cases or over a third of all adverse reports were attributed to the Byetta injectable. This represents 263 cases of pancreatitis, 71 for pancreatic cancer, 95 for renal failure, and 41 for thyroid cancer.
It was noted by the ISMP that 63 percent of these adverse reports were not filed by medical practitioners but directly by patients. Further analysis by the group may not exactly be favorable to the Byetta drug. It was found out that for every 100,000 prescriptions, Byetta accounted for 40 cases which was very high compared to the other incretin-based medications.